Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

Mahteme, Haile; Heideman, Anne von; Grundmark, Birgitta; Tholander, Bengt; Påhlman, Lars; Glimelius, Bengt; Larsson, Rolf; Graf, Wilhelm; Nygren, Peter

doi:10.1016/j.ejso.2007.05.002

Cited by 19 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 One possible cause for such a high failure rate could be the marked differences in drug sensitivity between different PC types and between individuals with the same tumor types, as was found in a recent study of patient PC samples. 27 In conclusion, CRS ? HIPEC is a relatively safe treatment option in selected patients with PC that originates from gastrointestinal tract and gynecological malignancies, resulting in improved outcomes.…”

Section: Discussionmentioning

confidence: 94%

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

Yang

Hassan

et al. 2008

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

Yang

Hassan

et al. 2008

Ann Surg Oncol

View full text Add to dashboard Cite

show abstract

“…Ultimately, individual drug sensitivity of a tumour may be noteworthy to the same extent. Existing evidence supports a heterogeneous response of cytotoxic agents in peritoneal metastases samples in a variety of tumours [114]. Hence, drug choice depending on in vitro drug sensitivity testing may result in improved clinical outcome after HIPEC.…”

Section: Patient-tailored Drug Choicementioning

confidence: 99%

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Bree

Michelakis

Stamatiou

et al. 2017

Pleura and Peritoneum

View full text Add to dashboard Cite

Intraperitoneal chemotherapy is associated with a significant pharmacokinetic and pharmacodynamic benefit and can, alone or in combination with systemic chemotherapy (bidirectional chemotherapy), be used for treating primary and secondary peritoneal surface malignancies. Due to the peritoneal-plasma barrier, high intraperitoneal drug concentration can be achieved by intraperitoneal chemotherapy, whereas systemic concentration remains low. Bidirectional chemotherapy may provide in addition adequate drug concentrations from the side of the subperitoneal space to the peritoneal tumour nodules. Major pharmacological problems of intraperitoneal chemotherapy are limited tissue penetration and poor homogeneity of drug distribution to the entire seroperitoneal surface. Significant pharmacological determinants of intraperitoneal chemotherapy are choice of drug, drug dosage, solution volume, carrier solution, intra-abdominal pressure, temperature, duration, mode of administration, extent of peritonectomy and interindividual variability. Drugs most commonly applied for intraperitoneal chemotherapy include mitomycin C, cisplatin, carboplatin, oxaliplatin, irinotecan, 5-fluoruracil, gemcitabine, paclitaxel, docetaxel, doxorubicin, premetrexed and melphalan. The drugs and their doses that are used vary widely among centres. While the adequate drug choice for intraperitoneal and bidirectional chemotherapy is essential, randomized clinical trials to determine the most optimal drug or drug combination are lacking, and only eight retrospective comparative clinical studies are available. Further clinical pharmacological studies are required to determine the most effective drug regimen for intraperitoneal and bidirectional chemotherapy in various indications. In the future, reliable drug sensitivity testing and genetic profiling of peritoneal metastases will be needed for enabling patient-specific therapy.

show abstract

“…There is solid evidence supporting a tumor-specific heterogeneous activity of cytotoxic drugs in cell cultures of different tumors [94,95] . Mahteme et al [96] recently stated the same heterogeneous cytotoxic response of cytotoxic drugs in PC samples in a variety of tumors. The clinical implication of these data justifies further research towards an individualized selection of drugs in PC patients.…”

Section: Hyperthermiamentioning

confidence: 82%

Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

Sugarbaker

Speeten²,

Stuart³

2010

WJGO

View full text Add to dashboard Cite

show abstract

Heterogeneous activity of cytotoxic drugs in patient samples of peritoneal carcinomatosis

Cited by 19 publications

References 20 publications

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival in Selected Patients with Peritoneal Carcinomatosis from Abdominal and Pelvic Malignancies: Results of 21 Cases

Pharmacological principles of intraperitoneal and bidirectional chemotherapy

Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

Contact Info

Product

Resources

About